31 results
425
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
21 Jun 22
Business combination disclosure
8:00am
approach $115 million of fully - committed equity financing provided to OmniAb Successful track record of building sustainable growth healthcare
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
21 Jun 22
Regulation FD Disclosure
6:19am
approach $115 million of fully - committed equity financing provided to OmniAb Successful track record of building sustainable growth healthcare
425
EX-99.3
rx52ou55 7x
23 Mar 22
Business combination disclosure
5:29pm
425
EX-99.2
m6xk4ttr5ffc
23 Mar 22
Business combination disclosure
5:29pm
8-K
EX-99.2
xszav6zq 4plbu910
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.3
m5do lkiy
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.1
59hwqi
13 Aug 14
Ligand Prices Offering of $225 Million of Convertible Senior Notes
12:00am
8-K
EX-99.1
mgdhbwyi2y375 r9ltzn
11 Aug 14
Ligand Announces Proposed Offering of $225 Million of Convertible Senior Notes
12:00am
8-K
EX-99.1
ifwscy4xvl9z95hl
11 Feb 14
Ligand Reports Fourth Quarter and Full Year 2013 Financial Results
12:00am
8-K
EX-99.1
a85wsz 0i7un9fk
4 Dec 13
Ligand Raises Fourth Quarter and Full Year 2013 Financial Forecast
12:00am
8-K
EX-99.1
b9mmh0v79 syjq
30 Oct 13
Ligand Reports Third Quarter Financial Results
12:00am
8-K
EX-99.1
n8d38q7 ezmki83
24 Jul 13
Ligand Signs License Agreement with Ethicor for Oral Lasofoxifene
12:00am
8-K
EX-99.1
6m2h2f7me8hy053
22 Jul 13
Ligand Signs Global License Agreement with Azure for Lasofoxifene
12:00am
8-K
EX-99.1
n3ho3wfluruw20 9xs2
20 Jun 13
Ligand Raises Ownership Limit for BVF Partners to 25% of Shares Outstanding
12:00am
8-K
EX-99.1
2nxbb
8 May 13
Ligand Reports First Quarter Financial Results
12:00am